PROS1 and COVID-19: reported a marked increase in autoantibody reactivities in COVID-19 patients as compared to uninfected individuals reflected by a higher prevalence of autoantibodies against immunomodulatory proteins (including cytokines, chemokines, complement components and cell-surface proteins) (31).